Get the Stockscreener App
1.30
9.72%
-0.14
After Hours:
1.30
Medicinova Inc stock is traded at $1.30, with a volume of 117.96K.
It is down -9.72% in the last 24 hours and down -19.75% over the past month.
MediciNova Inc is a biopharmaceutical company. The company acquires and develops small-molecule therapeutics for the treatment of diseases with unmet medical needs with a specific focus on the U.S. market. Its products portfolio includes therapeutics such as MN-001, MN-166, MN-221 etc. The firm's strategies are to focus its developing activities on therapeutics for neurological disorders and fibrotic diseases.
See More
Previous Close:
$1.44
Open:
$1.41
24h Volume:
117.96K
Relative Volume:
1.51
Market Cap:
$63.99M
Revenue:
$134.60K
Net Income/Loss:
$-11.81M
P/E Ratio:
-5.3964
EPS:
-0.2409
Net Cash Flow:
$-10.05M
1W Performance:
-14.47%
1M Performance:
-19.75%
6M Performance:
+0.78%
1Y Performance:
-18.24%
1-Day Range:
$1.29
$1.41
1-Week Range:
$1.29
$1.55
52-Week Range:
$1.13
$1.96
Medicinova Inc Stock (MNOV) Company Profile
Name
Medicinova Inc
Sector
Industry
Phone
858-373-1500
Address
4275 EXECUTIVE SQUARE, LA JOLLA, CA
Compare MNOV vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MNOV
Medicinova Inc
|
1.30 | 70.88M | 134.60K | -11.81M | -10.05M | -0.2409 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.11 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Medicinova Inc Stock (MNOV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-10-21 | Initiated | Maxim Group | Buy |
| Mar-25-19 | Resumed | B. Riley FBR | Buy |
| Mar-28-18 | Initiated | B. Riley FBR, Inc. | Buy |
| Apr-18-17 | Initiated | Credit Suisse | Outperform |
| Jan-04-13 | Reiterated | Ladenburg Thalmann | Buy |
| May-24-12 | Downgrade | MLV & Co | Buy → Hold |
| Oct-18-11 | Reiterated | MLV Capital | Buy |
| Jun-22-11 | Initiated | Global Hunter Securities | Buy |
| May-12-10 | Initiated | Wedbush | Outperform |
| Nov-12-08 | Reiterated | Ladenburg Thalmann | Buy |
| May-15-08 | Initiated | Rodman & Renshaw | Mkt Outperform |
| Jul-09-07 | Initiated | Punk, Ziegel & Co | Buy |
View All
Medicinova Inc Stock (MNOV) Latest News
Can MediciNova Inc continue delivering strong returnsMarket Activity Recap & Weekly Setup with ROI Potential - baoquankhu1.vn
MediciNova, Inc. (NASDAQ:MNOV) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
MediciNova (MNOV) Price Target Increased by 11.11% to 10.20 - Nasdaq
Breakout Watch: What analysts say about MediciNova Inc stockGDP Growth & Daily Growth Stock Investment Tips - baoquankhu1.vn
Market Moves: Can MediciNova Inc continue delivering strong returns2025 Stock Rankings & Risk Managed Trade Strategies - baoquankhu1.vn
MediciNova: Q4 Earnings Snapshot - Stamford Advocate
MediciNova, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
MediciNova (NASDAQ:MNOV) Posts Quarterly Earnings Results, Beats Estimates By $0.05 EPS - MarketBeat
Aug PreEarnings: What analysts say about MediciNova Inc stockJuly 2025 Setups & Daily Profit Focused Stock Screening - baoquankhu1.vn
Can MediciNova Inc. continue delivering strong returnsJuly 2025 EndofMonth & Long-Term Safe Return Strategies - mfd.ru
MediciNova reports preliminary 2025 financial results in Tokyo filing By Investing.com - Investing.com India
MediciNova Financial Report: Q4 & Annual 2025 ResultsLoss & Revenue FiguresNews and Statistics - IndexBox
MediciNova reports preliminary 2025 financial results in Tokyo filing - Investing.com
4875.T MediciNova (JPX) JPY 254.00 pre-earnings 19 Feb: catalysts to watch - Meyka
MediciNova, Inc. (NASDAQ:MNOV) Short Interest Update - MarketBeat
MediciNova (MNOV) Projected to Post Earnings on Wednesday - MarketBeat
Does MediciNova Inc. have strong fundamentalsRisk Management & Fast Exit and Entry Trade Guides - mfd.ru
MediciNova (NASDAQ:MNOV) Shares Pass Above 200-Day Moving AverageHere's What Happened - MarketBeat
MediciNova (NASDAQ:MNOV) Shares Pass Above 200-Day Moving Average – Here’s What Happened - Defense World
RSI Check: Is MediciNova Inc a stock for growth or value investorsQuarterly Portfolio Summary & Weekly Top Performers Watchlists - baoquankhu1.vn
Performance Recap: Is MediciNova Inc backed by strong institutional buyingLong Setup & Daily Profit Maximizing Tips - baoquankhu1.vn
MediciNova (MNOV) Price Target Increased by 28.57% to 9.18 - Nasdaq
Drug Developer Uncovers Excellent Progress in 200-Patient ALS Study - streetwisereports.com
Trading Action: Is MediciNova Inc. a stock for growth or value investorsBond Market & Verified Momentum Stock Ideas - baoquankhu1.vn
Biopharma Reaches 50% Enrollment in New ALS Drug Program - streetwisereports.com
MediciNova, Inc. (NASDAQ:MNOV) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
D. Boral Capital Reaffirms “Buy” Rating for MediciNova (NASDAQ:MNOV) - Defense World
MediciNova's (MNOV) Buy Rating Reaffirmed at D. Boral Capital - MarketBeat
MediciNova reaches 50% enrollment milestone in ALS drug study By Investing.com - Investing.com Nigeria
MediciNova Announces 100 Patients Enrolled in SEANOBI Study Expanded-Access-Program (EAP) Evaluating MN‑166 (ibudilast) in ALS patients - The Manila Times
MediciNova reaches 50% enrollment milestone in ALS drug study - Investing.com
ALS patients gain wider access as MediciNova trial reaches 100 enrollees - stocktitan.net
MediciNova (NASDAQ:MNOV) Shares Pass Above 200 Day Moving AverageWhat's Next? - MarketBeat
Institution Moves: What are the risks of holding Real Messenger CorporationTrade Ideas & Consistent Return Investment Signals - baoquankhu1.vn
MNOVMediciNova Reports Third Quarter 2011 Results - ADVFN
Dip Buying: Can MediciNova Inc continue delivering strong returnsTrade Signal Summary & Short-Term High Return Ideas - baoquankhu1.vn
MediciNova Announces Additional Analyses from Completed Clinical Trial of MN-166 (ibudilast) in ALS Presented at the 30th Int... - ADVFN
MediciNova (NASDAQ:MNOV) Share Price Crosses Above 200 Day Moving AverageShould You Sell? - MarketBeat
MediciNova (NASDAQ:MNOV) Share Price Crosses Above 200 Day Moving Average – Should You Sell? - Defense World
Price Action: How sensitive is MediciNova Inc to inflationMarket Activity Recap & Stepwise Entry/Exit Trade Alerts - baoquankhu1.vn
Aug Patterns: Why MediciNova Inc. stock could benefit from AI revolutionMarket Growth Summary & Long-Term Capital Growth Strategies - Bộ Nội Vụ
Rate Hike: Why MediciNova Inc. stock could benefit from AI revolution2025 Trading Recap & Accurate Buy Signal Alerts - Bộ Nội Vụ
Columbia University/New York State Psychiatric Institute and MediciNova Report Preliminary Safety and Efficacy of Ibudilast in H - ADVFN
MediciNova Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-001 for Triglyceride Synthesis in the Liver - ADVFN
FDA Grants Fast Track Designation for MediciNova's MN-166 (ibudilast) for the Treatment of Methamphetamine Dependence - ADVFN
Insider Buy: Will MediciNova Inc stock outperform value stocksJuly 2025 Action & Low Volatility Stock Recommendations - moha.gov.vn
Why MediciNova Inc. stock could benefit from AI revolutionMarket Trend Report & Expert Approved Momentum Trade Ideas - Улправда
Will MediciNova Inc. stock beat EPS estimatesPortfolio Gains Summary & Weekly High Conviction Trade Ideas - Улправда
MediciNova Receives a Notice of Allowance for a Method of Treating Drug Addiction or Dependence - ADVFN
Whale Trades: Why MediciNova Inc. stock could benefit from AI revolutionBear Alert & AI Driven Price Forecasts - Улправда
Is MediciNova Inc. stock a good choice for value investors2025 Support & Resistance & Precise Swing Trade Alerts - Улправда
Medicinova Inc Stock (MNOV) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.69%
0.68%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):